US FDA panel votes to keep controversial asthma indications for two drugs
This article was originally published in SRA
Executive Summary
US Food and Drug Administration advisory committee members have recommended that long-acting beta-2 adrenergic agonist (LABA) combination products should continue to be used for asthma, but the single-agent LABAs salmeterol and formoterol should be stripped of their current indications because of increased risks of asthma-related death and exacerbations with monotherapy1.